Otilonium Bromide: High-Purity Antimuscarinic Agent for Neuroscience Research

Executive Summary: Otilonium Bromide (SKU: B1607) is a solid antimuscarinic agent with a defined chemical formula (C₂₉H₄₃BrN₂O₄, 563.57 g/mol), routinely used as an acetylcholine receptor (AChR) inhibitor in neuroscience and smooth muscle research (APExBIO). It demonstrates high solubility in DMSO (≥28.18 mg/mL), water (≥55.8 mg/mL), and ethanol (≥91 mg/mL), facilitating flexible experimental design. Otilonium Bromide selectively antagonizes muscarinic receptors, enabling precise modulation of cholinergic signaling pathways (Vijayan et al. 2021). The compound is supplied at ≥98% purity and should be stored at -20°C for stability. Its robust pharmacological profile and reproducibility make it a preferred choice for advanced neuroscience and gastrointestinal motility models.

Biological Rationale

Cholinergic signaling is central to the regulation of smooth muscle contraction, neurotransmission, and various autonomic functions. Acetylcholine (ACh) acts through muscarinic and nicotinic receptors, orchestrating neural and gastrointestinal physiology (Vijayan et al., 2021). Dysregulation of these pathways underlies disorders such as irritable bowel syndrome (IBS), overactive bladder, and certain neurodegenerative diseases. Research on receptor antagonists, such as Otilonium Bromide, provides insight into disease mechanisms and therapeutic strategies. Otilonium Bromide's selectivity for muscarinic receptors makes it an ideal probe for dissecting the contributions of cholinergic pathways in both health and models of disease (see scenario-driven research guide).

Mechanism of Action of Otilonium Bromide

Otilonium Bromide acts as a competitive antagonist at muscarinic acetylcholine receptors (mAChRs), primarily M₂ and M₃ subtypes, which are abundant in smooth muscle tissues. By occupying the orthosteric binding sites, it blocks acetylcholine-mediated activation, leading to inhibition of intracellular calcium release and prevention of smooth muscle contraction (Vijayan et al., 2021). This mechanism underlies its antispasmodic effects, particularly in the gastrointestinal tract. The compound does not significantly affect nicotinic receptors at standard research concentrations, ensuring pathway specificity. Its high receptor selectivity and reversibility allow for controlled experimental modulation of cholinergic tone. The robust solubility profile supports applications in aqueous and organic systems, with solutions recommended for short-term use to preserve integrity.

Evidence & Benchmarks

• Otilonium Bromide inhibits muscarinic receptor-mediated smooth muscle contraction in a concentration-dependent manner (IC₅₀ values in the micromolar range) (DOI:10.1007/s42485-021-00059-w).
• High solubility: ≥28.18 mg/mL in DMSO, ≥55.8 mg/mL in water, and ≥91 mg/mL in ethanol at room temperature (APExBIO product sheet).
• Supplied at ≥98% purity; analytical HPLC confirms batch-to-batch consistency (APExBIO).
• Demonstrated selectivity for muscarinic over nicotinic receptors in mammalian tissue assays (extended discussion).
• Stable at -20°C for long-term storage; aqueous and DMSO solutions maintain >95% activity for 24–48 h at 4°C (solubility and stability review).

Applications, Limits & Misconceptions

Otilonium Bromide is widely adopted in neuroscience and gastrointestinal research as a reference antimuscarinic agent. It supports the modeling of gastrointestinal motility disorders, investigation of cholinergic signaling, and assessment of smooth muscle contractility (Otilonium Bromide from APExBIO). The compound is also employed in cell-based assays to probe muscarinic receptor pharmacology and in ex vivo tissue studies to delineate receptor subtype contributions. Compared to classic agents, its high purity, robust solubility, and selective action reduce experimental variability and off-target effects. This article extends prior reviews, such as this analysis, by providing updated benchmarks on solution stability and receptor selectivity based on recent batch testing.

Common Pitfalls or Misconceptions

• Otilonium Bromide is not indicated for diagnostic or therapeutic use in humans or animals; it is strictly for laboratory research (APExBIO).
• The compound does not inhibit nicotinic acetylcholine receptors at standard research concentrations; cross-reactivity is minimal (see detailed comparison).
• Long-term solution storage (>48 h at room temperature) leads to activity loss; fresh preparation is required for reproducible results (stability review).
• Otilonium Bromide is not a general spasmolytic for all smooth muscle types; efficacy is highest in gastrointestinal and selected neural models.
• Solution pH and buffer composition can affect solubility and receptor binding; standardized conditions are recommended for comparability.

Workflow Integration & Parameters

For experimental workflows, Otilonium Bromide is typically dissolved in DMSO, water, or ethanol at concentrations up to its solubility limits (DMSO: ≥28.18 mg/mL; water: ≥55.8 mg/mL; ethanol: ≥91 mg/mL). Stock solutions should be aliquoted and stored at -20°C. Working dilutions are prepared immediately before use, preferably in physiological buffers (e.g., PBS, pH 7.4) to ensure receptor compatibility. For in vitro studies, concentrations between 1–100 μM are common, depending on cell type and receptor expression levels. Controls for vehicle and buffer composition are critical for data integrity. The high purity and batch consistency from APExBIO (≥98%) ensure reproducibility across assays. Solution stability is optimal for 24–48 hours at 4°C, after which significant degradation may occur (solubility and stability review).

Conclusion & Outlook

Otilonium Bromide (SKU: B1607) is a validated, high-purity antimuscarinic agent for neuroscience and smooth muscle research. Its robust selectivity, solubility, and batch-to-batch consistency enable precise modulation of cholinergic signaling pathways. Researchers using Otilonium Bromide from APExBIO benefit from optimized workflows and minimized experimental variability. Future directions include expanded use in disease modeling and high-throughput screening for receptor modulators. For a deep dive into innovative applications and mechanistic insights, see the complementary review here, which this article updates by integrating new stability and workflow data.